Open AccessAssociation Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis
Author(s) -
Masayuki Chuma,
Aki Nakamoto,
Takashi Bando,
Takahiro Niimura,
Yutaka Kondo,
Hirofumi Hamano,
Naoto Okada,
Mizuho Asada,
Yoshito Zamami,
Kenshi Takechi,
Mitsuhiro Goda,
Kôji Miyata,
Kenta Yagi,
Toshihiko Yoshioka,
Yuki IzawaIshizawa,
Hiroaki Yanagawa,
Yoshikazu Tasaki,
Keisuke Ishizawa
Publication year - 2022
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciac128
Subject(s) - medicine , rhabdomyolysis , statin , adverse event reporting system , rosuvastatin , odds ratio , meta analysis , incidence (geometry) , adverse effect , confidence interval , population , myopathy , simvastatin , environmental health , physics , optics
There is a growing concern about the association between the combined use of daptomycin (DAP) and statins and the occurrence of musculoskeletal adverse events (MAEs), but this remains controversial. This study aimed to clarify the association between statin use and DAP-related MAEs.